Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

PURPOSE: In COLUMBUS part 1, patients with advanced BRAF(V600)-mutant melanoma were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice a day (COMBO450), vemurafenib 960 mg twice a day, or encorafenib 300 mg once daily (ENCO300). As previously reported, COMBO450 imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Robert, Caroline, Flaherty, Keith T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564308/
https://www.ncbi.nlm.nih.gov/pubmed/37506329
http://dx.doi.org/10.1200/JCO.22.02322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564308/
https://www.ncbi.nlm.nih.gov/pubmed/37506329
http://dx.doi.org/10.1200/JCO.22.02322

Ejemplares similares